CTSO on Nasdaq
Cytosorbents
Logo: cytosorbents.com5
American medical technology company
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey. CytoSorbents sells a cytokine adsorbing column ("CytoSorb" which received CE mark approval in 2011) — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.3 Its shares trade on Nasdaq under the symbol CTSO.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 20, 2026.
Overview
Compare with ClearPoint Neuro, Inc., RETRACTABLE TECHNOLOGIES INC or UTAH MEDICAL PRODUCTS INC, or pick any stock.
- TickerCTSO on Nasdaq1
- IndustryCritical care1
- HeadquartersMonmouth Junction1
- Websitecytosorbents.com
- Incorporated inDE6
- Business address305 College Road East, Princeton, Nj 085406
- Filer categoryNon-accelerated filer, Smaller reporting company6
- Legal formCorporation4
- LEI549300VI8WO8GK5QK7934
- StatusActive4
- LEI statusLapsed (not renewed)4
- Registered addressC/O United Corporate Services, Inc., 19904 Dover, United States4
See how the biggest companies compare on our leaderboards
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
71.5%Gross margin8
-39.8%Operating margin8
-22.1%Net margin8
4.1%Revenue growth, 20258
-138.9%Return on equity8
2.82×Debt to equity8
-$12.5MFree cash flow8
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue23¢$10.6M
- Selling, general and admin76¢$35.6M
- Income tax1¢$401.0K
Out of $37.1M in revenue.8 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue, net | $37.1M | $35.6M |
| Cost of goods sold | $10.6M | $10.7M |
| Gross profit | $26.5M | $24.9M |
| Research and development, net of grant income | $5.1M | $7.6M |
| Selling, general and administrative | $35.6M | $33.7M |
| Restructuring | $510.0K | |
| Total operating expenses | $41.2M | $41.3M |
| Loss from operations | -$14.7M | -$16.5M |
| Interest expense, net | -$2.6M | -$1.4M |
| Gain (loss) on foreign currency transactions | $9.3M | -$4.2M |
| Loss on abandoned patents | -$559.0K | -$334.0K |
| Total other income (expense), net | $6.2M | -$6.0M |
| Loss before benefit from income taxes | -$8.6M | -$22.4M |
| Benefit from income taxes | $401.0K | $1.7M |
| Net loss | -$8.2M | -$20.7M |
| Basic net loss per common share (in dollars per share) | -$0.13 | -$0.38 |
| Diluted net loss per common share (in dollars per share) | -$0.13 | -$0.38 |
| Weighted average number of shares of common stock outstanding, basic (in shares) | 62.2M shares | 54.4M shares |
| Weighted average number of shares of common stock outstanding, diluted (in shares) | 62.2M shares | 54.4M shares |
| Foreign currency translation adjustment, net of tax | -$7.2M | $3.7M |
| Comprehensive loss | -$15.4M | -$17.0M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2019-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $6.2M | $3.3M | ||
| Restricted cash, current | $5.0M | |||
| Accounts receivable, net of allowances of $164 and $158 at December 31, 2025 and 2024, respectively | $7.5M | $7.3M | ||
| Inventories - net | $5.3M | $2.7M | ||
| Prepaid expenses and other current assets | $1.6M | $3.3M | ||
| Total current assets | $20.6M | $21.6M | ||
| Property and equipment - net | $7.8M | $9.0M | ||
| Restricted cash | $1.5M | $1.5M | ||
| Right-of-use asset | $10.9M | $11.5M | ||
| Patents - net | $3.2M | $3.7M | ||
| Other assets | $53.0K | $50.0K | ||
| Total Assets | $44.2M | $47.4M | ||
| Accounts payable | $2.9M | $3.3M | ||
| Accrued expenses and other current liabilities | $6.3M | $6.0M | ||
| Lease liability - current portion | $541.0K | $453.0K | ||
| Total current liabilities | $9.7M | $9.8M | ||
| Lease liability, net of current portion | $11.9M | $12.4M | ||
| Long-term debt, net of debt discount | $16.7M | $14.0M | ||
| Total Liabilities | $38.3M | $36.3M | ||
| Common Stock, Par Value $0.001, 100,000,000 shares authorized; and 62,804,305 and 54,830,146 shares issued and outstanding at December 31, 2025 and 2024, respectively | $63.0K | $55.0K | ||
| Additional paid-in capital | $321.0M | $310.8M | ||
| Accumulated other comprehensive income (loss) | -$3.0M | $4.3M | ||
| Accumulated deficit | -$312.2M | -$304.0M | ||
| Total Stockholders' Equity | $5.9M | $11.1M | $23.5M | |
| Total Liabilities and Stockholders' Equity | $44.2M | $47.4M | ||
| Grants and accounts receivable, allowances | $164.0K | $158.0K | ||
| Preferred Stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred Stock, shares authorized | 5.0M shares | 5.0M shares | 5.0M shares | |
| Preferred Stock, shares issued | 0 shares | 0 shares | ||
| Preferred Stock, shares outstanding | 0 shares | 0 shares | ||
| Common Stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common Stock, shares authorized | 100.0M shares | 100.0M shares | ||
| Common Stock, shares issued | 62.8M shares | 54.8M shares | ||
| Common Stock, shares outstanding | 62.8M shares | 54.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2019-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $6.2M | $3.3M | ||
| Restricted cash, current | $5.0M | |||
| Accounts receivable, net of allowances of $164 and $158 at December 31, 2025 and 2024, respectively | $7.5M | $7.3M | ||
| Inventories - net | $5.3M | $2.7M | ||
| Prepaid expenses and other current assets | $1.6M | $3.3M | ||
| Total current assets | $20.6M | $21.6M | ||
| Property and equipment - net | $7.8M | $9.0M | ||
| Restricted cash | $1.5M | $1.5M | ||
| Right-of-use asset | $10.9M | $11.5M | ||
| Patents - net | $3.2M | $3.7M | ||
| Other assets | $53.0K | $50.0K | ||
| Total Assets | $44.2M | $47.4M | ||
| Accounts payable | $2.9M | $3.3M | ||
| Accrued expenses and other current liabilities | $6.3M | $6.0M | ||
| Lease liability - current portion | $541.0K | $453.0K | ||
| Total current liabilities | $9.7M | $9.8M | ||
| Lease liability, net of current portion | $11.9M | $12.4M | ||
| Long-term debt, net of debt discount | $16.7M | $14.0M | ||
| Total Liabilities | $38.3M | $36.3M | ||
| Common Stock, Par Value $0.001, 100,000,000 shares authorized; and 62,804,305 and 54,830,146 shares issued and outstanding at December 31, 2025 and 2024, respectively | $63.0K | $55.0K | ||
| Additional paid-in capital | $321.0M | $310.8M | ||
| Accumulated other comprehensive income (loss) | -$3.0M | $4.3M | ||
| Accumulated deficit | -$312.2M | -$304.0M | ||
| Total Stockholders' Equity | $5.9M | $11.1M | $23.5M | |
| Total Liabilities and Stockholders' Equity | $44.2M | $47.4M | ||
| Grants and accounts receivable, allowances | $164.0K | $158.0K | ||
| Preferred Stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred Stock, shares authorized | 5.0M shares | 5.0M shares | 5.0M shares | |
| Preferred Stock, shares issued | 0 shares | 0 shares | ||
| Preferred Stock, shares outstanding | 0 shares | 0 shares | ||
| Common Stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common Stock, shares authorized | 100.0M shares | 100.0M shares | ||
| Common Stock, shares issued | 62.8M shares | 54.8M shares | ||
| Common Stock, shares outstanding | 62.8M shares | 54.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$8.2M | -$20.7M |
| Accrued final fee | $111.0K | |
| Amortization of debt discount | $820.0K | $265.0K |
| Amortization of loan costs | $116.0K | |
| Amortization of patents | $262.0K | $235.0K |
| Depreciation and amortization | $1.2M | $1.3M |
| Amortization of right-of-use asset | $135.0K | $174.0K |
| Write off of inventory | $253.0K | |
| Bad debt expense | $40.0K | $115.0K |
| Loss on abandoned patents | $559.0K | $334.0K |
| Write off of fixed assets | $104.0K | |
| Foreign currency transaction (gains) losses | -$9.3M | $4.2M |
| Stock-based compensation | $2.8M | $3.8M |
| Grants and accounts receivable | $423.0K | -$1.7M |
| Inventories | -$2.5M | $500.0K |
| Prepaid expenses and other current assets | $1.8M | -$1.4M |
| Other assets | $2.0K | $1.0K |
| Accounts payable and accrued expenses | -$706.0K | -$1.8M |
| Net cash used in operating activities | -$12.4M | -$14.4M |
| Purchases of property and equipment | -$164.0K | -$284.0K |
| Disposal of property and equipment | $76.0K | |
| Patent costs | -$327.0K | -$385.0K |
| Net cash used in investing activities | -$415.0K | -$669.0K |
| Proceeds from long-term debt | $2.5M | $15.0M |
| Repayment of long-term debt | -$5.0M | |
| Payment of final fee | -$150.0K | |
| Payment of loan costs | -$698.0K | |
| Proceeds from rights offering, net | $5.4M | |
| Cash for exercise of warrants, net | $1.4M | |
| Equity contributions - net of fees incurred | $179.0K | |
| Net cash provided by financing activities | $9.3M | $9.3M |
| Effect of exchange rates on cash | $1.5M | -$85.0K |
| Net change in cash, cash equivalents, and restricted cash | -$2.0M | -$5.9M |
| Cash paid during the year for interest | $2.1M | $1.3M |
| Warrants issued in connection with modification of long-term debt | $627.0K | $691.0K |
| Capital expenditures included in accounts payable | $8.0K | |
| Settlement of accrued bonuses with restricted stock units | $198.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Cytosorbents sits at the top of its group. 6 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Cytosorbents
- AVENIR CORP Filed SCHEDULE 13G/A on Cytosorbents, latest Feb 13, 2026 (9 filings since Dec 13, 2021)
- Avenue Venture Opportunities Fund, L.P. Filed SCHEDULE 13G on Cytosorbents, latest May 28, 2025
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Cytosorbents, latest Apr 30, 2025 (4 filings since Feb 9, 2022)
- Skylands Capital, LLC Filed SCHEDULE 13G on Cytosorbents, latest Apr 17, 2025 (4 filings since Feb 7, 2023)
- Thomas A. Satterfield Jr. Filed SCHEDULE 13G on Cytosorbents, latest Jan 17, 2025
- Granahan Investment Management, LLC Filed SC 13G/A on Cytosorbents, latest Nov 14, 2024 (2 filings since Feb 14, 2024)
- Cytosorbents Monmouth Junction, New Jersey, United States
- CytoSorbents Europe GmbH Subsidiary · Germany
- CytoSorbents France SAS Subsidiary · France
- CytoSorbents Medical Canada Inc. Subsidiary · Canada
- CytoSorbents Medical Inc. Subsidiary · Delaware, United States
- CytoSorbents Switzerland GmbH Subsidiary · Switzerland
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Cytosorbents reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $13.0M8 Dec 31, 2025 | $13.2M8 Dec 31, 2024 | −2.0% |
| Accumulated depreciation | $5.1M8 Dec 31, 2025 | $4.2M8 Dec 31, 2024 | +21.8% |
| Property and equipment, net | $7.8M8 Dec 31, 2025 | $9.0M8 Dec 31, 2024 | −13.1% |
| Operating-lease assets (leased space) | $10.9M8 Dec 31, 2025 | $11.5M8 Dec 31, 2024 | −5.1% |
Investments
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated amortization | $1.4M8 Dec 31, 2025 | $1.3M8 Dec 31, 2024 | +13.8% |
| Finite-lived intangibles, net | $3.2M8 Dec 31, 2025 | $3.7M8 Dec 31, 2024 | −13.3% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $5.3M8 Dec 31, 2025 | $2.7M8 Dec 31, 2024 | +93.2% |
| Raw materials | $751.0K8 Dec 31, 2025 | $570.0K8 Dec 31, 2024 | +31.8% |
| Work in process | $1.0M8 Dec 31, 2025 | $503.0K8 Dec 31, 2024 | +101.6% |
| Finished goods | $3.5M8 Dec 31, 2025 | $1.7M8 Dec 31, 2024 | +112.5% |
Properties, in its own words
We currently operate one facility in Princeton, New Jersey and two facilities in Berlin, Germany as follows:
1. · In March 2021, we entered into a lease agreement for a new 48,511 square foot operating facility at 305 College Road East, Princeton, New Jersey, which contains office, laboratory, manufacturing and warehouse space. The lease commenced in April 2021 and expires in March 2037. As of December 31, 2025, our monthly base rent is approximately $124,000.
The rest of Item 2
2. · Our office facility leases in Berlin, Germany requires combined base rent payments amounting to approximately $12,100 per month. The initial lease term of both leases ends August 31, 2031. In addition, the Company is obligated to monthly operating expenses of approximately $3,000 per month.
3. · Our warehouse facility lease in Berlin, Germany commenced on April 1, 2021 and requires monthly payments of base rent of approximately $7,800 through its expiration on March 31, 2031.
In the opinion of management, the leased properties are adequately insured, are in good condition and suitable for the conduct of our business. We also collaborate with numerous institutions, universities and commercial entities who conduct research and testing of our products at their facilities.
Item 2 of the 10-K filed Mar 30, 2026.16
Leadership
Who has led Cytosorbents, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerJoseph G. Bowes Jul 7, 2006 to Jul 7, 200617
- Chief executive officerAl Kraus Jul 10, 2006 to Jun 27, 200818
- PresidentVincent Capponi May 7, 2020 to now19
- PresidentJoseph G. Bowes Jul 7, 2006 to Jul 7, 200617
- PresidentAl Kraus Jul 10, 2006 to Jun 27, 200818
- Chief financial officerPeter J. Mariani Aug 16, 2024 to now20
- Chief financial officerAlex D'Amico Aug 15, 2023 to Aug 15, 202321
- Chief financial officerKathleen P. Bloch Jul 17, 2013 to Apr 4, 202422
- Chief financial officerThomas Bocchino Dec 3, 2012 to Dec 3, 201223
- Chief financial officerJoseph G. Bowes Jul 7, 2006 to Jul 7, 200617
- Chief financial officerDavid Lamadrid Jul 10, 2006 to Sep 9, 201124
- Chief operating officerVincent Capponi Jul 10, 2006 to now25
Board members and other officers (12)
- OfficerVincent Capponi Jun 21, 2022 to Apr 5, 202326
- Chief Medical OfficerEfthymios Deliargyris May 5, 2020 to now27
- Chief Medical OfficerRobert Hawes Bartlett Jan 23, 2009 to Feb 28, 201728
- Chief Medical OfficerJames F. Winchester Jul 10, 2006 to Jun 27, 200829
- Board memberAlan D. Sobel Apr 13, 2015 to now30
- Board memberMichael G. Bator Jul 15, 2015 to now31
- Board memberVincent Capponi Jul 17, 2013 to Jul 17, 201332
- Board memberJames T. Gunton Aug 22, 2008 to Apr 10, 201533
- Board memberMartin F. Whalen May 30, 2007 to Jan 3, 200834
- Board memberJoseph G. Bowes Jul 7, 2006 to Jul 7, 200617
- Board memberAl Kraus Jul 10, 2006 to Feb 8, 202318
- Board memberKurt Katz Jul 10, 2006 to Jun 27, 200835
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- CytoSorbents Europe GmbH Germany7
- CytoSorbents France SAS France7
- CytoSorbents Medical Canada Inc. Canada7
- CytoSorbents Medical Inc. Delaware7
- CytoSorbents Switzerland GmbH Switzerland7
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Sep 23, 20268-K Regulation FD disclosure; Other events36
- Sep 8, 20268-K Bylaws or fiscal year changed37
- Aug 14, 20268-K Shareholder vote38
- Aug 7, 20268-K Regulation FD disclosure39
- Aug 6, 20268-K Results of operations40
- Jul 6, 20268-K Listing notice or transfer41
- Jun 25, 20268-K Regulation FD disclosure42
- May 13, 20268-K Results of operations43
- Apr 2, 20268-K Listing notice or transfer44
- Mar 25, 20268-K Results of operations; Regulation FD disclosure45
- Nov 13, 20258-K Results of operations46
- Oct 3, 20258-K Listing notice or transfer47
- Jul 10, 2006New chief executive Al Kraus becomes CEO18
- Jul 7, 2006New chief executive Joseph G. Bowes becomes CEO17
Calendar
Coming up
- Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.80) a share, on Nov 13, 2025.48
When it reported results
- Aug 6, 2026Reported quarterly or annual results40
- May 13, 2026Reported quarterly or annual results43
- Mar 25, 2026Reported quarterly or annual results45
- Nov 13, 2025Reported quarterly or annual results46
- May 14, 2025Reported quarterly or annual results49
- Mar 31, 2025Reported quarterly or annual results50
- Mar 21, 2025Reported quarterly or annual results51
- Mar 4, 2025Reported quarterly or annual results52
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
270 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 99 major events, 99 insider forms, 23 large holders, 28 other. The latest 20:
- Sep 23, 20268-K EDGAR
- Sep 16, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 16, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 16, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 9, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 8, 20268-K EDGAR
- Aug 14, 20268-K EDGAR
- Aug 7, 20268-K EDGAR
- Aug 6, 20268-K EDGAR
- Aug 6, 202610-Q EDGAR
- Jul 6, 20268-K EDGAR
- Jun 25, 2026ARS EDGAR
- Jun 25, 2026DEFA14A EDGAR
- Jun 25, 2026DEF 14A EDGAR
- Jun 25, 20268-K EDGAR
- Jun 16, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 15, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 11, 2026PRE 14A EDGAR
- May 13, 202610-Q EDGAR
- May 13, 20268-K EDGAR
The 270 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
41 open-market trades by officers, directors and large owners since October 2021: 41 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Chan Phillip P.Chief Executive Officer | Buy | 3,774 | $6.00 | $22.6K | Form 4 |
| Sep 15, 2026 | Sobel Alan D.Director | Buy | 2,500 | $6.10 | $15.3K | Form 4 |
| Sep 14, 2026 | Capponi VincentPresident and COO | Buy | 2,073 | $6.05 | $12.5K | Form 4 |
| Sep 4, 2026 | Chan Phillip P.Chief Executive Officer | Buy | 200,000 | $0.35 | $70.0K | Form 4 |
| Jun 15, 2026 | MARIANI PETER JChief Financial Officer | Buy | 100,000 | $0.44 | $44.0K | Form 4 |
| Jun 15, 2026 | Chan Phillip P.Chief Executive Officer | Buy | 10,333 | $0.43 | $4.4K | Form 4 |
| Jun 12, 2026 | Chan Phillip P.Chief Executive Officer | Buy | 251,136 | $0.40 | $100.5K | Form 4 |
| Dec 13, 2024 | MARIANI PETER JChief Financial Officer | Buy | 20,000 | $0.96 | $19.2K | Form 4 |
| Dec 12, 2024 | MARIANI PETER JChief Financial Officer | Buy | 20,000 | $0.89 | $17.8K | Form 4 |
| Dec 11, 2024 | MARIANI PETER JChief Financial Officer | Buy | 11,363 | $0.89 | $10.1K | Form 4 |
| Dec 13, 2023 | Sobel Alan D.Director | Buy | 22,557 | $1.33 | $30.0K | Form 4 |
| Dec 13, 2023 | Deliargyris EfthymiosChief Medical Officer | Buy | 22,557 | $1.33 | $30.0K | Form 4 |
| Dec 13, 2023 | Capponi VincentPresident and COO | Buy | 18,797 | $1.33 | $25.0K | Form 4 |
| Dec 13, 2023 | BATOR MICHAEL G.Director | Buy | 37,594 | $1.33 | $50.0K | Form 4 |
| Dec 13, 2023 | Jones Edward RaymondDirector | Buy | 7,519 | $1.33 | $10.0K | Form 4 |
| Dec 13, 2023 | BLOCH KATHLEEN P.Chief Financial Officer | Buy | 37,594 | $1.33 | $50.0K | Form 4 |
| Dec 13, 2023 | Kim JinyDirector | Buy | 7,519 | $1.33 | $10.0K | Form 4 |
| Dec 13, 2023 | Chan Phillip P.Chief Executive Officer | Buy | 75,188 | $1.33 | $100.0K | Form 4 |
| Aug 7, 2023 | BATOR MICHAEL G.Director | Buy | 2,000 | $3.17 | $6.3K | Form 4 |
| Aug 4, 2023 | BATOR MICHAEL G.Director | Buy | 1,000 | $3.23 | $3.2K | Form 4 |
All 41 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- AVENIR CORPSCHEDULE 13G/A, 9 filings Dec 13, 2021 to Feb 13, 202653
- Avenue Venture Opportunities Fund, L.P.SCHEDULE 13G, 1 filing May 28, 202554
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 9, 2022 to Apr 30, 202555
- Skylands Capital, LLCSCHEDULE 13G, 4 filings Feb 7, 2023 to Apr 17, 202556
- Thomas A. Satterfield Jr.SCHEDULE 13G, 1 filing Jan 17, 202557
- Granahan Investment Management, LLCSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202458
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Phillip P. ChanMD, PhD | 55 | $502.2K | $808.4K59 |
| 2025 | Vincent J. CapponiMS | 68 | $460.0K | $714.4K59 |
| 2025 | Efthymios N. DeliargyrisMD | 57 | $432.6K | $663.5K59 |
| 2025 | Peter J. Mariani | 62 | $442.0K | $659.9K59 |
| 2024 | Chief Executive Officer | $359.4K | $899.7K59 | |
| 2024 | President and Chief Operating Officer | $377.5K | $852.0K59 | |
| 2024 | Chief Medical Officer | $363.3K | $813.4K59 | |
| 2024 | Chief Financial Officer | $152.0K | $584.8K59 |
SEC filer profile
How Cytosorbents is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCytosorbents Corp2
- CIK0001175151
- Employer ID (EIN)98-037379316
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company16
- Incorporated inDelaware16
- Fiscal year endsDecember 312
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus2
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
- Business address305 College Road East, Princeton, NJ 085402
- Phone973-329-88852
- Shares outstanding62,842,748 as of Jul 31, 202614
- Public float$60.6M as of Jun 30, 202516
- AuditorWithumSmith+Brown, PC, East Brunswick, New Jersey PCAOB ID 100; it also attests to the company’s internal control over financial reporting16
- On EDGAR sinceMar 29, 20042
- Filings977 in all: 4 (361), 8-K (285), 10-Q (56), 3 (26), 10-K (18), EFFECT (15), DEFA14A (14), 424B5 (13)2
All 53 form types
DEF 14A (13), S-1/A (13), SC 13G (13), UPLOAD (13), 10QSB (10), CORRESP (10), SB-2/A (10), SC 13G/A (9), 424B3 (7), POS AM (7), S-1 (6), S-8 (6), 5 (5), ARS (5), SCHEDULE 13G (5), NT 10-K (4), NT 10-Q (4), S-3 (4), 10KSB (3), PRE 14A (3), S-3/A (3), SCHEDULE 13G/A (3), 4/A (2), 424B1 (2), CT ORDER (2), D (2), DEF 14C (2), FWP (2), PRE 14C (2), REGDEX (2), SB-2 (2), SC 13D (2), 10-K/A (1), 10KSB/A (1), 10QSB/A (1), 144 (1), 3/A (1), 424B4 (1), 8-A12B (1), 8-A12G (1), 8-K/A (1), CERTNAS (1), RW (1), S-1MEF (1), S-8 POS (1)
- Latest filingsAnnual report (10-K) Mar 30, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Jun 25, 2026
Latest 8-K (8-K) Sep 23, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 par value | CTSO | Nasdaq |
From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).16
Risk factors and legal proceedings
The risks Cytosorbents names in Item 1A of its 10-K filed Mar 30, 2026: 39 risks under these headings, as written.16
- Risks Related to our Business and our Industry
- We have a history of losses and may incur future losses.
- We may require additional capital in the future to fund our operations and failure to raise additional capital or generate cash flows necessary to maintain our operations could reduce our ability to compete successfully and harm our results of operations.
- A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and operations.
- Our operating results are subject to seasonal fluctuation.
- Although historically we have been a research and development company, we are currently commercializing some of our products. There can be no assurance that we will be successful in continuing and expanding commercial operations or balancing our research and development activities with our commercialization activities.
- If users of our products are unable to obtain adequate reimbursement from third-party payers, or if reimbursement is not available in specific countries, or if new restrictive legislation is adopted, market acceptance of our products may be limited and we may not achieve anticipated revenues.
- We depend upon key personnel who may terminate their employment with us at any time.
- We may not be successful in obtaining the FDA’s or Health Canada’s authorization and successful commercialization for DrugSorb-ATR in the U.S. or Canada, respectively.
- Acceptance of our medical devices in the marketplace is uncertain, and failure to achieve market acceptance will prevent or delay our ability to generate revenues.
- If we are unable to obtain and maintain patent protection for our products and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and product candidates similar or identical to ours, and our ability to successfully commercialize our products and product candidates may be adversely affected.
- We may face litigation from third parties claiming that our products infringe on their intellectual property rights or seek to challenge the validity of our patents.
The other 28 risks
- The expiration or loss of patent protection may adversely affect our future revenues and operating earnings.
- We have received and continue to seek additional regulatory approvals of our products and product candidates, but the approval process involves lengthy and costly clinical studies and is, in large part, not in our control. The failure to obtain government approvals, internationally or domestically, for our products and product candidates, or to comply with ongoing governmental regulations could prevent, delay or limit introduction or sale of our products and result in the failure to achieve revenues or maintain our operations.
- If we fail to maintain the CE Mark in the European Union, we will not be able to commercially sell and market CytoSorb.
- We may pursue various indications for our product candidates, and they may be subject to different FDA regulatory pathways for marketing authorization, and under the jurisdiction of different FDA review divisions within the FDA.
- Adverse economic conditions and political or regulatory developments could materially and adversely affect our business.
- Clinical study results for our CytoSorb and/or DrugSorb-ATR device may not be indicative of our future clinical study results, and we cannot assure you that any clinical study results will lead to results sufficient for necessary regulatory clearances or product sales. Additionally, clinical and pre-clinical data is susceptible to varying interpretations, which could delay, limit, reduce, or prevent additional regulatory clearances or product sales.
- We are and will be exposed to product liability risks, and clinical and preclinical liability risks, which could place a substantial financial burden upon us should we be sued.
- Certain university and other relationships are important to our business and may potentially result in conflicts of interests.
- Although we have significant manufacturing experience and capabilities, we may not be able to manufacture sufficient quantities at an acceptable cost or quality, or without shut-downs or delays.
- We depend on a limited number of suppliers for chemicals, other raw materials, and molded parts used in the development and manufacture of our products. Although we typically second source and validate the quality of chemicals, raw materials, and molded parts any change in the availability of these components, or availability of single sourced materials, without an alternative source may result in lengthy delays or disruptions in manufacturing if we need to change or cannot identify a supplier for any reason which could have a material impact on our business and results of operations.
- Due to our limited resources for marketing, sales and distribution, and our reliance on many different distributors, we may be unsuccessful in our efforts to successfully commercialize our products in one or more countries.
- Our results of operations can be significantly affected by foreign currency fluctuations and regulations.
- If we are unable to convince physicians and other health care providers as to the benefits of our products, we may incur delays or additional expense in our attempt to establish market acceptance.
- The market for our products is rapidly changing and competitive, and new devices and drugs, which may be developed by others, could impair our ability to maintain and grow our business and remain competitive.
- Our business could be harmed by adverse economic conditions in Germany, our primary geographical market, or by economic and/or political instability in Germany, the EU or elsewhere caused by various factors.
- Economic downturns, international trade disruptions, wars, terrorism, and geopolitical conflicts could materially and adversely affect our business and operating results.
- We could be adversely affected by violations of the Foreign Corrupt Practices Act and similar worldwide anti-bribery laws.
- We are subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.
- Cyberattacks and other security breaches could compromise our proprietary and confidential information which could harm our business and reputation.
- Our failure to comply with data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.
- Risks Connected to Our Securities
- We are not in compliance with the continued listing standards of the Nasdaq Stock Market LLC (“Nasdaq”), and our common stock could be delisted if we do not regain compliance with listing standards within time frame required by the Nasdaq staff, which could have a material adverse effect on the liquidity of our common stock.
- Our common stock is listed on the Nasdaq Stock Market LLC (“Nasdaq”). On October 2, 2025, we were notified that we were not in compliance with the Nasdaq’s continued listing requirements relating to the minimum average closing price per share of our common stock, because the average closing price of our common stock over a consecutive 30 trading-day period was below $1.00 per share (the “Minimum Bid Price Requirement”).
- The Company intends to actively monitor the closing bid price of its common stock and will consider its options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq listing standards. If the Company is unable to regain compliance with the Minimum Bid Price Requirement, our common stock will be subject to the Nasdaq’s suspension and delisting procedures.
- During this time, our common stock will continue to be listed on the Nasdaq, subject to our compliance with other Nasdaq continued listing requirements. However, there can be no assurance about our ability to regain compliance with the Nasdaq’s minimum price condition within the applicable cure periods.
- The price of our common stock has been highly volatile due to factors that will continue to affect the price of our stock.
- Directors, executive officers and principal stockholders own a significant percentage of the shares of common stock, which will limit your ability to influence corporate matters.
- Our Board of Directors’ authority to issue additional securities and anti-takeover provisions in our governing documents under Delaware law could adversely affect the rights of our common stockholders and discourage or delay a change in control.
- In our previous Form 10K, we identified a material weakness in our internal control over financial reporting, which could, if not effectively remediated, result in additional restatements of our financial statements, and a failure to meet our reporting and financial obligations, each of which could adversely affect our results of operations and financial condition.
Legal proceedings
From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact because of defense and settlement costs, diversion of management resources and other factors.
On March 5, 2024, a former employee, filed a complaint against us in the Superior Court of New Jersey, Law Division, Mercer County, alleging retaliatory termination in breach of the New Jersey Conscientious Employee Protection Act (“CEPA”). Following further discussion, the parties agree there was a professional misunderstanding between them and have amicably resolved the litigation.
The opening of Item 3, Legal Proceedings.16
Links
- Websitecytosorbents.com1
- WikipediaCytosorbents Corporation
- WikidataQ17182820
- SEC EDGARCIK 1175151
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataCytosorbents on Wikidata
- 2SEC EDGARCytosorbents filings on SEC EDGAR
- 3WikipediaCytosorbents on Wikipedia
- 4
- 5Company websiteCytosorbents logo
- 6SEC EDGARCytosorbents filings on SEC EDGAR
- 7
- 8SEC EDGARCytosorbents 10-K for fiscal 2025
- 9SEC EDGARCytosorbents 10-K for fiscal 2019
- 10SEC EDGARCytosorbents 10-K for fiscal 2020
- 11SEC EDGARCytosorbents 10-K for fiscal 2021
- 12SEC EDGARCytosorbents 10-K for fiscal 2023
- 13SEC EDGARCytosorbents 10-Q for fiscal 2026
- 14SEC EDGARCytosorbents 10-Q for fiscal 2026
- 15SEC EDGARCytosorbents 10-K for fiscal 2019
- 16
- 17
- 18SEC EDGARAl Kraus, Chief executive officer
- 19SEC EDGARVincent Capponi, President
- 20
- 21
- 22
- 23
- 24
- 25
- 26SEC EDGARVincent Capponi, Officer
- 27
- 28
- 29
- 30SEC EDGARAlan D. Sobel, Board member
- 31SEC EDGARMichael G. Bator, Board member
- 32SEC EDGARVincent Capponi, Board member
- 33SEC EDGARJames T. Gunton, Board member
- 34SEC EDGARMartin F. Whalen, Board member
- 35SEC EDGARKurt Katz, Board member
- 36
- 37SEC EDGARBylaws or fiscal year changed
- 38SEC EDGARShareholder vote
- 39SEC EDGARRegulation FD disclosure
- 40SEC EDGARResults of operations
- 41SEC EDGARListing notice or transfer
- 42SEC EDGARRegulation FD disclosure
- 43SEC EDGARResults of operations
- 44SEC EDGARListing notice or transfer
- 45
- 46SEC EDGARResults of operations
- 47SEC EDGARListing notice or transfer
- 48NasdaqNasdaq calendar
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59